Plain-English translation of NCT02836158 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a combination treatment called R-IDARAM, given both as a systemic drug and directly into the spinal fluid, can help older adults with primary central nervous system lymphoma (a cancer that starts in the brain or surrounding tissues). The researchers want to see how well the medication works, how long people survive, and what side effects occur when radiotherapy is delayed.
Elderly patients with brain lymphoma have limited treatment options, and older treatment approaches can be very hard on the body. This trial is exploring whether this new medication combination can be effective while potentially reducing the need for immediate radiation therapy.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination as part of your cancer treatment plan. The treatment involves systemic chemotherapy (given intravenously) combined with immunochemotherapy delivered directly into your spinal fluid. You would have regular clinic visits to receive treatment, undergo blood tests and imaging scans to monitor your response, and be followed for survival outcomes over time. The researchers will track how well the treatment works and any side effects you experience.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Navy General Hospital, Beijing
Enrollment target
~100 participants
Started
September 2010
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
60 Years – 75 Years
Last updated on clinicaltrials.gov in September 2020.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Liren Qian, M.D.
Navy General Hospital, Beijing
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.